var data={"title":"Trabectedin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Trabectedin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/379870?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=trabectedin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Trabectedin: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45600777\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Yondelis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11392727\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Yondelis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618429\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618545\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Prior to each treatment cycle, ANC should be &ge;1,500/mm<sup>3</sup>, platelets &ge;100,000/mm<sup>3</sup> total bilirubin &le; ULN, and alkaline phosphatase, ALT, AST, and CPK &le;2.5 times ULN.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Premedications:</i> Administer dexamethasone 20 mg IV 30 minutes prior to each infusion. Trabectedin is associated with a moderate emetic potential (Hesketh 2017; Roila 2016); additional antiemetics may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Soft tissue sarcoma, unresectable/metastatic:</b> IV: 1.5 mg/m<sup>2</sup> continuous infusion over 24 hours once every 3 weeks; continue until disease progression or unacceptable toxicity (Demetri 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian cancer, relapsed, platinum sensitive (off-label use):</b> IV: 1.1 mg/m<sup>2</sup> over 3 hours every 3 weeks (in combination with doxorubicin liposomal), continue as long as clinical benefit is demonstrated or until disease progression or confirmed complete response or for 2 or more cycles beyond complete response (Monk 2010; Monk 2012; Poveda 2011). Delay treatment and/or reduce the trabectedin dose (to 0.9 mg/m<sup>2</sup>, then to 0.75 mg/m<sup>2</sup>) for toxicities (doxorubicin liposomal may also require modification), consider discontinuing if a second dose reduction is not tolerated (Monk 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618546\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618547\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute or ESRD: There is no dosage adjustment provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Hemodialysis is not expected to enhance elimination of trabectedin. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618548\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Hepatic impairment prior to treatment: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (bilirubin 1 to 1.5 times ULN and any AST or ALT): No initial dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate impairment (bilirubin 1.5 to 3 times ULN and AST or ALT &lt;8 times ULN: Reduce dose from 1.5 mg/m<sup>2</sup> to 0.9 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: (bilirubin &gt;3 to 10 times ULN and any AST or ALT): Do not administer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Hepatotoxicity during treatment:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recommended dose reduction levels in patients with mild or moderate hepatic impairment at baseline (once a dose is reduced it should not be increased in subsequent cycles):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First dose reduction: 1.2 mg/m<sup>2</sup> once every 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second dose reduction: 1 mg/m<sup>2</sup> once every 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First dose reduction: 0.6 mg/m<sup>2</sup> once every 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second dose reduction: 0.3 mg/m<sup>2</sup> once every 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total bilirubin &gt;ULN: Delay dose for up to 3 weeks and reduce the next dose by one dose level</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST or ALT &gt;2.5 times ULN: Delay dose for up to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST or ALT &gt;5 times ULN during prior cycle: Delay dose for up to 3 weeks and reduce the next dose by one dose level</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alkaline phosphatase &gt;2.5 times ULN: Delay dose for up to 3 weeks and reduce the next dose by one dose level</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe liver dysfunction (bilirubin 2 times ULN and AST or ALT 3 times ULN with alkaline phosphatase &lt;2 times ULN in prior treatment cycle in patients with normal hepatic function at baseline): Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Exacerbation of hepatic dysfunction in patients with preexisting moderate impairment: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adverse reactions with trabectedin administered at 1 mg/m<sup>2</sup> (in patients with normal hepatic function or preexisting mild hepatic impairment) or at 0.3 mg/m<sup>2</sup> (in patients with preexisting moderate hepatic impairment) and requiring further dose reduction: Permanently discontinue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344284\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer: </i> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618549\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Soft tissue sarcoma:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recommended dose reduction levels (once a dose is reduced it should not be increased in subsequent cycles):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First dose reduction: 1.2 mg/m<sup>2</sup> once every 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second dose reduction: 1 mg/m<sup>2</sup> once every 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hematologic toxicity:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;1,500/mm<sup>3</sup>: Delay dose for up to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;1,000/mm<sup>3</sup> with fever or infection or &lt;500/mm<sup>3</sup> lasting &gt;5 days during prior cycle: Delay dose for up to 3 weeks and reduce the next dose by one dose level</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &lt;100,000/mm<sup>3</sup>: Delay dose for up to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &lt;25,000/mm<sup>3</sup> during prior cycle: Delay dose for up to 3 weeks and reduce the next dose by one dose level</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nonhematologic toxicity: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Creatine phosphokinase &gt;2.5 times ULN: Delay dose for up to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Creatine phosphokinase &gt;5 times ULN during prior cycle: Delay dose for up to 3 weeks and reduce the next dose by one dose level</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Decreased left ventricular ejection fraction (LVEF): Less than the lower limit of normal (LLN) or clinical evidence of cardiomyopathy: Delay dose for up to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Decreased LVEF: Absolute decrease of 10% or more from baseline and less than the LLN or clinical evidence of cardiomyopathy during prior cycle: Delay dose for up to 3 weeks and reduce the next dose by one dose level</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Other nonhematologic toxicity: Grade 3 or 4: Delay dose for up to 3 weeks and reduce the next dose by one dose level</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adverse reactions with trabectedin administered at 1 mg/m<sup>2</sup> (in patients with normal hepatic function or preexisting mild hepatic impairment) or 0.3 mg/m<sup>2</sup> (in patients with preexisting moderate hepatic impairment; refer to dosing in hepatic impairment) and requiring further dose reduction: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capillary leak syndrome: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persistent adverse events requiring a delay of more than 3 weeks: Permanently discontinue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45600778\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Yondelis: 1 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45600776\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618552\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">Trabectedin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Infuse through a central line with a 0.2 micron polyethersulfone filter. Infusion must be completed within 30 hours of reconstitution. Premedicate with a corticosteroid (eg, dexamethasone 20 mg IV) 30 minutes prior to treatment; additional antiemetics may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Soft tissue sarcoma: Single-agent therapy: Infuse as a continuous infusion over 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ovarian cancer (off-label use): Combination therapy with doxorubicin liposomal: Administer doxorubicin liposomal first (flush line with D<sub>5</sub>W) then follow with trabectedin infusion over 3 hours (Monk 2010).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133464\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7665303\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Soft tissue sarcoma: </b>Treatment of unresectable or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma) in patients who have received a prior anthracycline-containing regimen.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46205894\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Ovarian cancer, relapsed (platinum sensitive)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618424\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618510\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (69%), headache (25%), insomnia (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoalbuminemia (63%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (75%), vomiting (46%), constipation (37%), decreased appetite (37%), diarrhea (35%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (96%; grades 3/4: 19%), neutropenia (66%; grades 3/4: 43%), thrombocytopenia (59%; grades 3/4: 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (90%), increased serum AST (84%), increased serum alkaline phosphokinase (70%), hyperbilirubinemia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase (32% to 33%), arthralgia (15%), myalgia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (46%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Pulmonary embolism (&lt;10%), cardiomyopathy (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Hypoesthesia (&lt;10%), paresthesia (&lt;10%), peripheral neuropathy (&lt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Capillary leak syndrome, hepatotoxicity, rhabdomyolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618431\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known, severe hypersensitivity (including anaphylaxis) to trabectedin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Active serious or uncontrolled infection; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618508\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Anemia, neutropenia, and thrombocytopenia commonly occur; neutropenic fever and neutropenic sepsis (with fatalities) have been reported. The median onset for first occurrence of grade 3/4 neutropenia was 16 days (range: 8 days to ~10 months) and median time to recovery was 13 days (range: 3 days to ~2 months). Monitor blood counts prior to each dose and periodically throughout treatment cycle. Withhold treatment for neutrophil count &lt;1,500/mm<sup>3</sup>. Reduce dose (permanently) for life-threatening or prolonged severe neutropenia in the preceding cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Capillary leak syndrome: Capillary leak syndrome (CLS) has been reported, including serious cases resulting in death. Symptoms include hypotension, edema, and hypoalbuminemia; monitor for signs/symptoms of CLS. Discontinue if CLS develops and manage as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: Cardiomyopathy, including HF, decreased ejection fraction, diastolic dysfunction, or right ventricular dysfunction, has been observed; some events were grades 3 and 4. The median time to development of grades 3 and 4 cardiomyopathy was ~5 months (range: 1 to 15 months). Monitor left ventricular ejection fraction (LVEF) by echocardiogram or MUGA scan prior to treatment initiation and every 2 to 3 months until trabectedin is discontinued. Withhold treatment if LVEF is below the lower limit of normal (LLN); permanently discontinue for symptomatic cardiomyopathy or persistent ventricular dysfunction that does not recover to LLN within 3 weeks. Patients with a history of New York Heart Association class II, III, or IV heart failure or abnormal LVEF were excluded from the sarcoma study.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Infuse through a central line. Avoid extravasation. Extravasation of trabectedin with subsequent tissue necrosis requiring debridement has been reported; evidence of necrosis may be delayed up to 1 week after extravasation. There are no specific antidotes for trabectedin extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI events: Trabectedin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016). Nausea and vomiting are common; corticosteroid premedication (eg, dexamethasone) is recommended; other antiemetics may also be needed. Constipation and diarrhea (generally mild) also commonly occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity (including hepatic failure) may occur with trabectedin. Grade 3 and 4 LFT elevations (AST, ALT, total bilirubin, or alkaline phosphatase) occurred in over one-third of patients. The median onset for grade 3/4 ALT or AST elevations was 29 days (range: 3 days to 11.5 months) and the median time to resolution was 13 days (range: 4 days to ~4 months); some patients experienced complete resolution. Drug-induced liver injury (ALT or AST elevation &gt;3 times ULN, alkaline phosphatase &lt;2 times ULN, and total bilirubin &ge;2 times ULN) and ALT or AST elevations &gt;8 times ULN have been reported. Monitor LFTs prior to each dose (more frequently if clinically indicated); elevated LFTs may require treatment interruption, dose reduction, and/or discontinuation (based on severity and duration). Premedication with dexamethasone (4 mg twice daily the day prior to administration) has been reported to reduce the incidence of hepatotoxicity (Grosso 2006). Patients with bilirubin above the ULN or AST or ALT &gt;2.5 times the ULN were excluded from the sarcoma clinical trial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Symptoms of hypersensitivity reactions have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rhabdomyolysis: Trabectedin may cause rhabdomyolysis and musculoskeletal toxicity (some fatal). Creatine phosphokinase (CPK) elevations occurred in nearly one-third of patients receiving trabectedin; grade 3 and 4 CPK elevations, some complicated by renal failure, occurred. The median time to first occurrence of grade 3 or 4 CPK elevation was 2 months (range: 1 to 11.5 months) and the median time to complete resolution was 14 days (range: 5 to 30 days). Monitor CPK levels prior to each dose; withhold treatment for CPK levels &gt;2.5 times ULN; discontinue permanently if rhabdomyolysis occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Pulmonary embolism has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300158\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11399607\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9513&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the hepatotoxic effect of Trabectedin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Trabectedin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Trabectedin.<b> Exceptions: </b>Grapefruit Juice.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Trabectedin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): May enhance the myopathic (rhabdomyolysis) effect of Trabectedin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Trabectedin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11392729\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Based on the mechanism of action, trabectedin may cause fetal harm if administered during pregnancy. Women of reproductive potential should use effective contraception during and for at least 2 months after treatment. Males with partners of reproductive potential should use effective contraception during and for at least 5 months following treatment. Trabectedin may cause decreased fertility in males and females.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11392731\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if trabectedin is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends discontinuing breastfeeding during trabectedin treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618554\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (baseline, prior to each dose, and periodically throughout treatment cycles); total bilirubin (prior to each cycle; more frequently if clinically indicated), ALT, AST, and alkaline phosphatase (prior to each cycle; more frequently if clinically indicated); renal function (baseline and during treatment); CPK (prior to each treatment cycle), evaluate LVEF via MUGA or echocardiogram (baseline and every 2 to 3 months); monitor for signs/symptoms of capillary leak syndrome; monitor infusion site for signs/symptoms of extravasation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7618550\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Trabectedin is a marine-derived compound (alkylating agent) which blocks the cell cycle at the G<sub>2</sub>/M phase by covalently binding to the minor DNA groove, bending the helix toward the major groove and altering DNA transcription (Garcia-Carbonero 2005). Affects activity of DNA binding proteins, transcription factors and DNA repair mechanism, leading to cell death.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11393776\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: &gt;5,000 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~97%; to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic; via CYP3A4</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~175 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (58%; only negligible amounts as unchanged drug); urine (6%; only negligible amounts as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45762832\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Yondelis Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $3,438.31</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961949\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Yondelis (AE, AR, AT, BE, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FR, GB, GR, GT, HK, HN, HR, IE, IL, IN, IS, IT, JO, JP, KR, LB, LT, LU, LV, MT, MY, NI, NL, NO, PA, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. <i>J Clin Oncol</i>. 2016;34(8):786-793.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/26371143/pubmed\" target=\"_blank\" id=\"26371143\">26371143</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Carbonero R, Supko JG, Maki RG, et al, &ldquo;Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study,&rdquo; <i>J Clin Oncol</i>, 2005, 23(24):5484-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/16110008/pubmed\" target=\"_blank\" id=\"16110008\">16110008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gronchi A, Bui BN, Bonvalot S, et al, &ldquo;Phase II Clinical Trial of Neoadjuvant Trabectedin in Patients With Advanced Localized Myxoid Liposarcoma,&rdquo; <i>Ann Oncol</i>, 2012, 23(3):771-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/21642514/pubmed\" target=\"_blank\" id=\"21642514\">21642514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. <i>Eur J Cancer</i>. 2006;42(10):1484-1490.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/16737808/pubmed\" target=\"_blank\" id=\"16737808\">16737808</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017:JCO2017744789. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Italiano A, Laurand A, Laroche A, et al. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma, <i>Cancer</i>, 2011, 117(15):3445-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/21287534/pubmed\" target=\"_blank\" id=\"21287534\">21287534</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le Cesne A, Blay JY, Judson I, et al, &ldquo;Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial,&rdquo; <i>J Clin Oncol</i>, 2005, 23(3):576-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/15659504/pubmed\" target=\"_blank\" id=\"15659504\">15659504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20516432\"></a>Monk BJ, Herzog TJ, Kaye SB, et al, &ldquo;Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer,&rdquo; <i>J Clin Oncol</i>, 2010, 28(19):3107-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/20516432/pubmed\" target=\"_blank\" id=\"20516432\">20516432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22541893\"></a>Monk BJ, Herzog TJ, Kaye SB, et al, &ldquo;Trabectedin Plus Pegylated Liposomal Doxorubicin (PLD) versus PLD in Recurrent Ovarian Cancer: Overall Survival Analysis,&rdquo; <i>Eur J Cancer</i>, 2012, 48(15):2361-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/22541893/pubmed\" target=\"_blank\" id=\"22541893\">22541893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo; <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perez-Ruixo JJ, Zannikos P, Hirankarn S, et al, &ldquo;Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743, Yondelis) in Cancer Patients,&rdquo; <i>Clin Pharmacokinet</i>, 2007, 46(10):867-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/17854236/pubmed\" target=\"_blank\" id=\"17854236\">17854236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20643862\"></a>Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. <i>Ann Oncol</i>. 2011;22(1):39-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/20643862/pubmed\" target=\"_blank\" id=\"20643862\">20643862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al.; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22541893\"></a>The National Institute for Occupational Safety and Health (NIOSH) notice. Centers for Disease Control and Prevention Web site. <a href=\"https://www.cdc.gov/niosh/docs/2016-161/default.html\" target=\"_blank\">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated April 10, 2017. Accessed June 8, 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/22541893/pubmed\" target=\"_blank\" id=\"22541893\">22541893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Theman TA, Hartzell TL, Sinha I, et al, &ldquo;Recognition of a New Chemotherapeutic Vesicant: Trabectedin (Ecteinascidin-743) Extravasation With Skin and Soft Tissue Damage,&rdquo; <i>J Clin Oncol</i>, 2009, 27(33):e198-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/19805684/pubmed\" target=\"_blank\" id=\"19805684\">19805684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed May 27, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yondelis (trabectedin) [prescribing information]. Horsham, PA: Janssen Products; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yondelis (trabectedin) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yovine A, Riofrio M, Blay JY, et al, &ldquo;Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients,&rdquo; <i>J Clin Oncol</i>, 2004, 22(5):890-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trabectedin-drug-information/abstract-text/14990645/pubmed\" target=\"_blank\" id=\"14990645\">14990645</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9513 Version 156.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45600777\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11392727\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7618429\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7618545\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7618546\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F7618547\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F7618548\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20344284\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F7618549\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45600778\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F45600776\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7618552\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133464\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7665303\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F46205894\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7618424\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7618510\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7618431\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7618508\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300158\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F11399607\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11392729\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11392731\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7618554\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7618550\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F11393776\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45762832\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961949\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9513|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=trabectedin-patient-drug-information\" class=\"drug drug_patient\">Trabectedin: Patient drug information \t</a></li></ul></div></div>","javascript":null}